Skip to content

Onyx Motion signs NBA’s Ben Gordon and launches Indiegogo crowdfunding campaign

Former Orlando Magic player new innovation director for basketball smartwatch app

This article is republished with the kind permission of Brianna Goldberg and our friends at U of T News.

Onyx-Motion-Swish-app-basketball-coach-1024x675UTEST company Onyx Motion has partnered with NBA shooting guard Ben Gordon to raise the calibre of digital basketball coaching offered by the company’s first-of-its-kind technology, a smartwatch app that offers on-court skills guidance. The company announced Gordon’s role in helping to further develop the app, called Swish, on July 8 when launching their Indiegogo campaign.

“We’re hoping to build a motion marketplace — a library of data, moves and audio tips from pro players,” said Onyx Motion co-founder and CEO Marissa Wu.

Onyx Motion’s Indiegogo crowdfunding campaign launch was covered by: TechVibes, Silicon Angle, IT Business.ca, Canadian Reviewer, Network World, GizMag and Sport Techie.

Swish uses smartwatch motion sensors to analyze athlete techniques and offer straightforward tips on how a player can improve.

“The Swish technology is bringing users closer to their favourite basketball player by giving them the opportunity to learn from them,” said Gordon. “I’m excited to work with the team on the further development of this one-of-a-kind experience and help players at any level improve their game.”

Continue Reading

Sunnybrook forms new industry partnership to advance WaveCheck technology

Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool

WavecheckTORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy.

This announcement was covered in Biotechnology Focus, Aunt Minnie.com (radiology blog), dotmed.com, Bio-Medicine.org, Bloomberg Business and Research Views.

The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck as a clinical tool that gives clinicians rapid, improved transparency to determine if breast cancer tumors are responding to chemotherapy.

WaveCheck is a clinical technique invented, refined and tested by Dr. Gregory Czarnota, chief of Radiation Oncology at Sunnybrook’s Odette Cancer Centre, and Michael C. Kolios, professor of Physics and associate dean, Research and Graduate Studies, in Ryerson University’s Faculty of Science. Their technology uses ultrasound to visually demonstrate whether chemotherapy is destroying a breast cancer tumour at the beginning of chemotherapy treatment in as little as one week. If applied to the clinic, this knowledge has the power to transform patient experience, since existing breast cancer patients typically wait until the end of treatment, anywhere from four to six months, to know if their tumor has responded.

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.
In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology shows promise as an accurate, efficient way to monitor tumour response, opening the door to tailored treatment.

The agreement leverages GE Healthcare’s extensive ultrasound technology and market expertise in bringing new ultrasound innovations to global hospitals and clinics with Sunnybrook’s leadership in oncology research and cancer care through the Odette Cancer Centre.

Continue Reading

Toronto Star features Minuum keyboard’s successful iPhone product launch

Whirlscape founders William Walmsley (left), Severin Smith and Xavier Snelgrove. The company is a graduate of the UTEST program's first cohort.
Whirlscape founders Will Walmsley (left), Severin Smith and Xavier Snelgrove. The company is a graduate of the UTEST program’s first cohort.

UTEST graduate Whirlscape was featured in Raju Mudhar’s Toronto Star article, “Toronto’s Whirlscape debuts tiny Minuum keyboard on iPhone,” which examines the company’s successful launch of their innovative, one-line keyboard for Apple’s iOS 8.

The UTEST program, co-directed by MaRS Innovation and the University of Toronto’s Innovations & Partnerships Office, gives nascent software companies start-up funding, office space, mentoring and business strategy support. Whirlscape was among the program’s first cohort.

The article was published October 6, 2014. Here’s an excerpt:

An Indiegogo success 18 months ago, the company created a tiny keyboard called Minuum for Android devices. Now, iOS and the vast Apple market beckoned. It required new hires, a couple months of round-the-clock development, and a practical rebuilding of their product from scratch so it could be ready to launch with iOS 8. All the work paid off: in the first two weeks of availability, they have sold more than 30,000 apps to the new iPhone audience.

Continue Reading

WaveCheck campaign part of new study on crowdfunding medical research

MI’s Fazila Seker also interviewed in National Post article on what prompts medical researchers to consider crowdfunding

WavecheckThe WaveCheck crowdfunding campaign, which raised $53,390 on Indiegogo to support clinical trials for a clinical technique invented by researchers at Sunnybrook Health Sciences Centre and Ryerson University, was included in a new Canadian-led study on the merits of crowdfunding to support cancer and rare diseases.

Crowdfunding drug development: The state of play in oncology and rare diseases,” was published in Drug Discovery Today‘s June issue.

MaRS Innovation has confirmed with lead author Professor Nick Dragojlovic of the University of British Columbia that WaveCheck was among the campaigns included in the study.

Continue Reading

WaveCheck breast cancer technology receives $100,000

OICR’s catalyst grant enables WaveCheck to open first partner site at MD Anderson Cancer Center in May

WavecheckTORONTO, April 8, 2014 — People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR).

The funding builds upon MaRS Innovation‘s Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over $50,000 from over 500 supporters worldwide in two months last fall.

Read Jane Gerster’s article for the Toronto Star about OICR’s catalyst grant for WaveCheck. This announcement was also covered in Metro, BetaKit and Council of Academic Hospitals of Ontario’s Catalyst newsletter.

WaveCheck, a clinical technique invented, refined and tested by scientists at Sunnybrook Health Sciences Centre and Ryerson University over 20 years, aims to show whether chemotherapy is actually destroying a breast cancer tumour at the beginning of chemotherapy treatment (in as little as four weeks), rather than at the end of treatment (typically four to six months).

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.
In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. As of March 2015, Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.

In early clinical testing, the non-invasive, image-guided technology has shown promise as an accurate, efficient way to monitor tumour response, opening the door to tailored treatment.

“This is a significant step towards achieving the goal of personalized medicine. The clinical trials will confirm that information provided by WaveCheck can determine if the treatment is the appropriate one or that other options should be chosen, sparing patients the side effects of treatments that will not likely be successful,” said Dr. Tom Hudson, OICR’s president and scientific director. “If successful, WaveCheck could become a standard tool in the cancer treatment of the future.”

Continue Reading

WaveCheck Indiegogo campaign co-directors featured in MedCity News article

wave
MI’s Fazila Seker and Elizabeth Monier-Williams, campaign co-directors for WaveCheck, were featured in a MedCity News article about successfully crowdfunding in the healthcare field.

MaRS Innovation’s Dr. Fazila Seker and Elizabeth Monier-Williams spoke with Deanna Pogorelc of MedCity News about how to define success for campaigns crowdfunding for technologies and research related to the medical field.

The article, in MedCity News‘ Hot Topics section, questions whether a crowdfunding campaign needs to reach its funding goal to be deemed successful.

Seker and Monier-Williams completed an Indiegogo crowdfunding campaign in December for WaveCheck, a clinical technique developed to let women and men know if their breast cancer chemotherapy is working within weeks of beginning treatment instead of months later when treatment has already ended.

Here’s an excerpt from the article:

Fazila Seker, the director of technology and venture development at commercialization agency MaRS Innovation, said that one of the trickiest things about the crowdfunding industry is the notion that these platforms have an established crowd that’s lurking around looking for the next best thing.

“You can’t rely entirely on that,” she said. “You need to go out there and do your research and create your own following.”

Continue Reading

Y Combinator-backed Whirlscape closes $500,000 seed funding round

Minuum keyboard creators accelerate wearable device input technology development

Screen Shot 2014-01-21 at 11.26.56 AM
Whirlscape, Inc., creators of the Minuum keyboard, closed an seed funding round of $500,000.

TORONTO, Canada (February 6, 2014) — Whirlscape Inc., creators of Minuum, “the little keyboard for big fingers,” have closed an investment seed round for just over $500,000 (USD). Y Combinator, FundersClub, BDC Venture Capital, and a dozen other prominent angel investors have contributed to the round.

Whirlscape’s plans for the capital involve innovating beyond its participation in Silicon Valley’s start-up accelerator Y Combinator. Whirlscape also aims to consolidate the success of its Minuum keyboard for Android touchscreen devices—available on Google Play—whose positive reviews have boosted sales since the New Year.

See articles of Whirlscape’s seed funding announcement by Darrell Etherington in TechCrunchIan Hardy in BetaKitRob Lewis in TechVibes and Global University Venturing.

Since launching the Minuum keyboard in 2013, Whirlscape has grown to a dedicated team of 10 working to enable new ways to type, and to unify input methods across the rapidly emerging field of wearable and ubiquitous computing devices such as smart watches and Google Glass. Whirlscape has recently demonstrated the Minuum keyboard working on Samsung’s Galaxy Gear smart watch.

“Our vision for the future of hyper-personalized input devices involves letting you choose your companion device for its input capabilities,” said Will Walmsley, CEO of Whirlscape. “By simplifying the concept of the keyboard, we allow text entry to occur in places where it was previously unthinkable, removing barriers to communication. Your keyboard can now be anywhere you want it to be, out of the way, yet immediately accessible.”

Whirlscape, Inc. was in the first cohort of UTEST, the MaRS Innovation and University of Toronto accelerator program for early-stage technologies. UTEST is now accepting applications for their third cohort.

Continue Reading

Council of Academic Hospitals features WaveCheck technology and crowdfunding campaign

waveThe Council of Academic Hospitals of Ontario’s online magazine highlighted WaveCheck on February 3, 2014 as a more personalized approach to cancer treatments because of the technology’s ability to effectively monitor chemotherapy response.

WaveCheck’s technology, invented by Dr. Gregory Czarnota of Sunnybrook Health Sciences Centre and Professor Michael C. Kolios of Ryerson University, allows women and men undergoing chemotherapy for breast cancer to know if their treatment is working at the beginning of treatment (within one to four weeks) rather than at the end of treatment (typically four to six months).

Here’s an excerpt from the article:

Breast cancer is the most common cancer among Canadian women, excluding non-melanoma skin cancers. It is the second leading cause of death from cancer in women in this country. The Canadian Cancer Society estimated that, in 2013, 65 Canadian women would be diagnosed with breast cancer every day, totaling 23,800 women a year; and 14 Canadian women would die from breast cancer every day, totaling 5,000 women a year. According to the Canadian Breast Cancer Foundation, one in nine Canadian women is expected to develop breast cancer during her lifetime; one in 29 will die from it.

Continue Reading
Back To Top